Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a U.S.-based radiopharmaceutical company focused on developing targeted alpha therapies for cancer. The company combines clinical-stage drug development with owned and operated manufacturing facilities in the United States to support production, testing, and future commercialization of its program candidates.

5.17

5.17

— Perspective Therapeutics, Inc.
%
Clinical-stage radiopharmaceutical programs90% Alpha-emitting oncology drug candidates in preclinical and clinical development.
Grant revenue10% Research support tied to work performed for the National Institutes of Health.

Perspective Therapeutics primarily serves cancer patients indirectly through hospitals, oncology centers, and clinical...

  • Clinical trial sitesprimary

    Hospitals and research centers that enroll patients and administer investigational radiopharmaceuticals in Phase 1/2 studies.

  • Government research sponsorsecondary

    The National Institutes of Health funds or supports research work that generates grant revenue.

  • Future oncology treatment centersemerging

    Cancer centers and nuclear medicine practices that could buy approved therapies for patient treatment.

The company is headquartered in the United States and operates manufacturing and development activities across several...

  • •Headquartered in the United States
  • •Somerset, New Jersey facility supports Northeastern U.S. supply
  • •Houston, Chicago, and Los Angeles sites expand manufacturing footprint
  • •U.S. clinical and commercial demand is the core operating geography
  • •No country-level revenue disclosure was provided in the excerpts

Perspective Therapeutics is building a vertically integrated radiopharmaceutical platform by advancing clinical assets,...

01
Advance clinical-stage radiopharmaceutical assetsshort-term

Clinical success is the main path to future product revenue and value creation.

02
Expand manufacturing and supply chain capacitymedium-term

Radiopharmaceuticals require specialized production, handling, and distribution infrastructure.

03
Prepare for commercializationmedium-term

Approved therapies will require manufacturing, distribution, and market access capabilities.

The company faces the typical risks of clinical-stage biotechnology, including trial failure, regulatory delays, and...

critical

Clinical development failure

The company’s value depends on proving safety and efficacy in human trials.

Scope
VMT01, VMT-α-NET, PSV359 and other candidates
Materiality
high
high

Regulatory approval risk

Even successful trials may not translate into marketing approval or timely labeling decisions.

Scope
All current and future program candidates
Materiality
high
high

Financing and dilution risk

The business is pre-commercial and may need repeated capital raises to fund R&D and capex.

Scope
ATM equity program and future financing needs
Materiality
high
high

Manufacturing and supply execution risk

Radiopharmaceutical production requires validated facilities, equipment, and tight logistics.

Scope
Somerset, Houston, Chicago, Los Angeles facilities
Materiality
high
Grant revenue recognition
Separates research support from future commercial product revenue
R&D expense capitalization versus expensing
Quarterly R&D volatility and comparability
Property, equipment, and lease accounting
Affects balance sheet asset values and future expense recognition
Fair value of short-term investments
Can affect other income and liquidity presentation

EyePoint, Inc.

EYPT · Laboratory Analytical Instruments

Outlook Therapeutics, Inc.

OTLK · Biological Products, (No Diagnostic Substances)

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

Tango Therapeutics, Inc.

TNGX · Pharmaceutical Preparations

: 29.4.2026